poisar

Stocks · News reference

Blackstone Life Sciences To Provide Johnson & Johnson With $750M In R&D Funding To Support Phase 3 Clinical Development Of OLN324, An Investigational Therapy For Serious Retinal Vascular Diseases

BenzingaBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncPrecedence Research

    Pharmaceutical Market to Reach USD 3.20 Trillion by 2035 as Obesity and Oncology Drugs Lead Growth and U.S. Pricing Deals and Tariffs Reshape Manufacturing

    The global pharmaceutical market is valued at USD 1.88 trillion in 2026 and is projected to reach USD 3.20 trillion by 2035 at a CAGR of 6.10%. Growth is concentrated in obesity and oncology therapies, with U.S. pricing deals and Section 232 tariffs reshaping manufacturing. North America holds 42% of the market, while companies with strong positions in GLP-1 medicines and cancer therapies are growing significantly faster than the market.

  2. Zacks Investment ResearchNa

    Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

    The iShares U.S. Pharmaceuticals ETF (IHE) is reviewed as a reasonable option for investors seeking broad exposure to the Healthcare-Pharma sector. With $1.69 billion in assets and a 0.37% expense ratio, the fund has delivered strong year-to-date returns of 28.8% and one-year returns of 35.48%. However, it carries higher risk with a beta of 0.47 and standard deviation of 17.13%. Top holdings include Eli Lilly (26.88%), Johnson & Johnson, and Royalty Pharma, with the top 10 holdings representing 81.09% of assets.

  3. Globenewswire IncNa

    Medline Inc. announces pricing of secondary offering of Class A common stock

    Medline Inc. announced the pricing of a secondary offering of 60 million Class A common shares at $35.50 per share by selling stockholders affiliated with Blackstone, Carlyle Group, Hellman & Friedman, GIC Private Limited, and Abu Dhabi Investment Authority. The offering is expected to close on November 23, 2026. Medline will not receive proceeds from the sale but has agreed to repurchase $200 million of its own stock and Common Units from the selling stockholders at the same price.

  4. Zacks Investment ResearchNa

    J&J to Acquire Ollin Biosciences: A Look at Its Recent Buyouts

    Johnson & Johnson announced a $2.2 billion acquisition of clinical-stage biotech Ollin Biosciences to expand its ophthalmology pipeline with OLN324, a phase III bispecific antibody for retinal diseases. Blackstone will fund $750 million of the phase III development. This acquisition is part of J&J's broader strategy of pursuing strategic M&A to strengthen its Innovative Medicine and MedTech businesses, following recent acquisitions of Firefly Bio, Intra-Cellular Therapies, Shockwave Medical, and Abiomed.